Caffeine withdrawal retains anticataleptic activity but Withania somnifera withdrawal potentiates haloperidol-induced catalepsy in mice.
The previous study showed that chronic treatment with Withania somnifera extract (WS) inhibited haloperidol-induced catalepsy. It is suggested that caffeine and WS may be useful adjuvants in pharmacotherapy of Parkinson's disease. There are no studies on the effect of haloperidol on mice withdrawn from caffeine or W. somnifera. We therefore studied the effect of a single administration of standardised WS containing 5.1% total withanolides (WS, 30 or 100 mg kg(-1) i.p.) and/or caffeine (3 mg kg(-1) i.p.) and withdrawal from 6 days treatment with WS and/or caffeine, on haloperidol-induced catalepsy in albino mice. Single administration of both WS and caffeine, used either alone or in combination, significantly inhibited catalepsy. Mice withdrawn from caffeine significantly inhibited haloperidol-induced catalepsy, but mice withdrawn from WS showed increased catalepsy. The study indicated that withdrawal from WS does not retain anticataleptic activity, and caffeine but not WS may be a good adjuvant in pharmacotherapy of Parkinson's disease.
Department of Pharmacology, Mahatma Gandhi Vidyamandir's Pharmacy Collge, Nashik, Maharashtra, India. kasture_sb@hotmail.com
Sanjay
S
Kasture
Shrikant
S
Barhate
Mahalaxmi
M
Mohan
Mauro
M
Ballero
Cinzia
C
Sanna
Andrea
A
Maxia
D000704:Analysis of Variance; D000818:Animals; D002110:Caffeine / Q000494:pharmacology*; D002375:Catalepsy / Q000139:chemically induced*; D006220:Haloperidol / Q000494:pharmacology*; D051379:Mice; D009420:Nervous System / Q000187:drug effects*; D010936:Plant Extracts / Q000494:pharmacology*; D032341:Withania / Q000737:chemistry*
D010936:Plant Extracts; D002110:Caffeine; D006220:Haloperidol